PUBLISHER: IMARC | PRODUCT CODE: 1467745
PUBLISHER: IMARC | PRODUCT CODE: 1467745
Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2024-2032
The global non-alcoholic steatohepatitis (NASH) market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.5 Billion by 2032, exhibiting a growth rate (CAGR) of 24.18% during 2024-2032. The rising prevalence of NASH, increasing awareness regarding early diagnosis and treatments, and the integration of artificial intelligence (AI) and machine learning (ML) technologies represent some of the key factors driving the market.
Non-alcoholic steatohepatitis (NASH) refers to a progressive non-alcoholic fatty liver disease (NAFLD) caused by insulin resistance, overweight, and metabolic syndrome. Its symptoms involve fatigue and weakness, weight loss, jaundice, itchy skin, spider veins, enlarged liver, lack of concentration, fluid accumulation, and abdominal discomfort, such as pain and swelling. It is diagnosed through multiple techniques, such as physical examination, blood test, liver biopsy, magnetic resonance imaging (MRI), ultrasound, and computed tomography (CT) scan. NASH treatment includes medication, liver transplant, and various lifestyle modifications, such as regular exercise, and healthy diets. These treatment methods aid in reducing liver fat accumulation, improving liver function, reducing inflammation, and minimizing liver damage. They also enhance patients' quality of life, improve long-term outcomes, and allow better management of other health problems, such as obesity and high blood pressure.
Non-Alcoholic Steatohepatitis (NASH) Market Trends:
The rising prevalence of NASH due to genetics, sedentary lifestyle, unhealthy eating habits, obesity, and type 2 diabetes is one of the key factors driving the market growth. In line with this, NASH treatments are widely adopted by patients to alleviate symptoms, increase lifespan, prevent premature death, improve liver health, and promote overall well-being, which in turn is providing a thrust to the market growth. Furthermore, the increasing awareness among the masses regarding early diagnosis and treatment of NASH to reduce healthcare expenses, eliminate the need for liver transplants, and prevent future complications, such as high blood pressure, cardiovascular diseases (CVDs), cancer, cirrhosis, and liver failure is providing an impetus to the market growth. Additionally, the utilization of non-invasive imaging techniques to monitor and diagnose NASH, such as MRI and transient elastography (TE), which, in turn, enhances patients' comfort, increases compliance, reduces the risk of complications, and improves clinical outcomes, is positively influencing the market growth. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) to develop personalized treatments, improve diagnosis accuracy, and predict disease progression is favoring the market growth. Moreover, the implementation of various government initiatives to provide access to high-quality treatment and support the development of advanced therapeutics is propelling the market growth. Other factors, including the rising geriatric population, increasing healthcare expenditure, extensive research and development (R&D) activities, significant growth in the healthcare industry, and the increasing demand for non-invasive treatment options, are anticipated to drive the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global non-alcoholic steatohepatitis (NASH) market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on drug type, disease cause, sales channel, and end user.
Drug Type Insights:
Vitamin E and Pioglitazone
Ocaliva
Elafibranor
Selonsertib
Cenicriviroc
Others
The report has provided a detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the drug type. This includes Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, and others. According to the report, vitamin E and pioglitazone represented the largest segment.
Disease Cause Insights:
Hypertension
Heart Disease
High Blood Lipid
Type 2 Diabetes
Obesity
A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the disease cause has also been provided in the report. This includes hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity. According to the report, obesity accounted for the largest market share.
Sales Channel Insights:
Hospital Pharmacy
Online Providers
Retail Pharmacy
A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the sales channel has also been provided in the report. This includes hospital pharmacy, online providers, and retail pharmacy. According to the report, retail pharmacy accounted for the largest market share.
End User Insights:
Hospitals
Clinics
Homecare Settings
A detailed breakup and analysis of the non-alcoholic steatohepatitis (NASH) market based on the end user has also been provided in the report. This includes hospitals, clinics, and homecare settings. According to the report, clinics accounted for the largest market share.
Regional Insights:
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for non-alcoholic steatohepatitis (NASH). Some of the factors driving the North America non-alcoholic steatohepatitis (NASH) market included the rising prevalence of NASH, increasing government initiatives, and rapid technological advancements.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global non-alcoholic steatohepatitis (NASH) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Algernon Pharmaceuticals, Galmed Pharmaceuticals Ltd, Intercept Pharmaceuticals Inc., Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report
- 1. How big is the global Non-Alcoholic Steatohepatitis (NASH) market?
- 2. What is the expected growth rate of the global Non-Alcoholic Steatohepatitis (NASH) market during 2024-2032?
- 3. What are the key factors driving the global Non-Alcoholic Steatohepatitis (NASH) market?
- 4. What has been the impact of COVID-19 on the global Non-Alcoholic Steatohepatitis (NASH) market?
- 5. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the drug type?
- 6. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the disease cause?
- 7. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the sales channel?
- 8. What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the end user?
- 9. What are the key regions in the global Non-Alcoholic Steatohepatitis (NASH) market?
- 10. Who are the key players/companies in the global Non-Alcoholic Steatohepatitis (NASH) market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Non-Alcoholic Steatohepatitis (NASH) Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Drug Type
- 6.1 Vitamin E and Pioglitazone
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Ocaliva
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Elafibranor
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Selonsertib
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Cenicriviroc
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
7 Market Breakup by Disease Cause
- 7.1 Hypertension
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Heart Disease
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 High Blood Lipid
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Type 2 Diabetes
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Obesity
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by Sales Channel
- 8.1 Hospital Pharmacy
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Online Providers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Retail Pharmacy
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Clinics
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Homecare Settings
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 Drivers, Restraints, and Opportunities
- 11.1 Overview
- 11.2 Drivers
- 11.3 Restraints
- 11.4 Opportunities
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Algernon Pharmaceuticals
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.2 Galmed Pharmaceuticals Ltd
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.3 Intercept Pharmaceuticals Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Zydus Lifesciences Limited
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.1 Algernon Pharmaceuticals
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
List of Figures
- Figure 1: Global: Non-Alcoholic Steatohepatitis Market: Major Drivers and Challenges
- Figure 2: Global: Non-Alcoholic Steatohepatitis Market: Sales Value (in Billion US$), 2018-2023
- Figure 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Billion US$), 2024-2032
- Figure 4: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Drug Type (in %), 2023
- Figure 5: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Disease Cause (in %), 2023
- Figure 6: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Sales Channel (in %), 2023
- Figure 7: Global: Non-Alcoholic Steatohepatitis Market: Breakup by End User (in %), 2023
- Figure 8: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Region (in %), 2023
- Figure 9: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 10: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 11: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 12: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 13: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 14: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 15: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 16: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 17: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 18: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 19: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 20: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 21: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 22: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 23: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 24: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 25: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 26: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 27: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 28: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 29: Global: Non-Alcoholic Steatohepatitis (Obesity) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 30: Global: Non-Alcoholic Steatohepatitis (Obesity) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 31: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 32: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 33: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 34: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 35: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 36: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 37: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 38: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 39: Global: Non-Alcoholic Steatohepatitis (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 40: Global: Non-Alcoholic Steatohepatitis (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 41: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 42: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 43: North America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 44: North America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 45: United States: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 46: United States: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 47: Canada: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 48: Canada: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 49: Asia-Pacific: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 50: Asia-Pacific: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 51: China: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 52: China: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 53: Japan: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 54: Japan: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 55: India: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 56: India: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 57: South Korea: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 58: South Korea: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 59: Australia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 60: Australia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 61: Indonesia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 62: Indonesia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 63: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 64: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 65: Europe: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 66: Europe: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 67: Germany: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 68: Germany: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 69: France: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 70: France: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 71: United Kingdom: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 72: United Kingdom: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 73: Italy: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 74: Italy: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 75: Spain: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 76: Spain: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 77: Russia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 78: Russia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 79: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 80: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 81: Latin America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 82: Latin America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 83: Brazil: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 84: Brazil: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 85: Mexico: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 86: Mexico: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 87: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 88: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 89: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million US$), 2018 & 2023
- Figure 90: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Breakup by Country (in %), 2023
- Figure 91: Middle East and Africa: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 92: Global: Non-Alcoholic Steatohepatitis Industry: Drivers, Restraints, and Opportunities
- Figure 93: Global: Non-Alcoholic Steatohepatitis Industry: Value Chain Analysis
- Figure 94: Global: Non-Alcoholic Steatohepatitis Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Non-Alcoholic Steatohepatitis Market: Key Industry Highlights, 2023 & 2032
- Table 2: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
- Table 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Disease Cause (in Million US$), 2024-2032
- Table 4: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Sales Channel (in Million US$), 2024-2032
- Table 5: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by End User (in Million US$), 2024-2032
- Table 6: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Region (in Million US$), 2024-2032
- Table 7: Global: Non-Alcoholic Steatohepatitis Market: Competitive Structure
- Table 8: Global: Non-Alcoholic Steatohepatitis Market: Key Players
